On August 22, 2018 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, reported that it will participate in two upcoming investor conferences (Press release, Halozyme, AUG 22, 2018, View Source [SID1234529026]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Helen Torley, president and chief executive officer of Halozyme, will participate in Citigroup’s 13th Annual Biotech Conference in Boston on Wednesday, September 5, 2018. Dr. Torley will represent Halozyme on a panel titled "Targeted Therapies Oncology – Aiming for the Bull’s Eye" at the conference.

On Thursday, September 6, 2018, Dr. Torley will present an overview of the company at the 2018 Wells Fargo Securities Healthcare Conference in Boston at 1:20 p.m. ET / 10:20 a.m. PT. A live audio webcast of the presentation will be available in the "Investors" section of Halozyme’s website at www.halozyme.com with an archived replay available for 90 days following the event.

On August 22, 2018 Varian (NYSE: VAR) reported its fourth quarter fiscal year 2018 earnings release date and upcoming investor meeting at the American Society for Radiation Oncology (ASTRO) Annual Meeting (Press release, Varian Medical Systems, AUG 22, 2018, View Source [SID1234529027]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth Quarter Fiscal Year 2018 Earnings

The Company will report results for the fourth quarter of fiscal year 2018 after market close on Wednesday, October 23, 2018. The news release will be followed by a teleconference available to all interested at 1:30 p.m. Pacific Time. To access the teleconference call and replay:

Teleconference: Access from within the U.S. by dialing 1-877-869-3847, and from outside the U.S. by dialing 1-201-689-8261.

Replay: Access from within the U.S. by dialing 1-877-660-6853 and from outside the U.S. by dialing 1-201-612-7415, and enter conference ID 13682642. The teleconference replay will be available until 5:00 p.m. Pacific Time, Thursday, October 25, 2018.

Webcast: To access the live webcast and replay, visit the company website at: www.varian.com/investors and click on the link for Fourth Quarter Earnings Results.

Varian Investor Meeting at ASTRO

Dow Wilson, chief executive officer, and members of the executive staff will be meeting with analysts and investors at the American Society for Radiation Oncology Annual Meeting in San Antonio on Tuesday, October 23, 2018 at 8:00 a.m. Central Time.

Information about the webcast of the company’s presentation will be available through a link on the company website at www.varian.com/investors.

To attend Varian’s ASTRO investor meeting, please RSVP to Katie Glenn at [email protected]. Please RSVP by October 1, 2018.

For automatic e-mail alerts regarding Varian news and events, investors can subscribe on the company website: View Source

On August 21, 2018 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) reported that the Company will participate in the following upcoming investment conferences (Press release, Inovio, AUG 21, 2018, View Source [SID1234529012]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rodman and Renshaw 20th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC
Presentation
Dr. J. Joseph Kim, President & CEO
September 5, 2018, 10:25 AM ET
New York, NY

Citi’s 13th Annual Biotech Conference
1×1 meetings only
September 6, 2018
Boston, MA

Cantor Fitzgerald 2018 Global Healthcare Conference
Presentation
Dr. J. Joseph Kim, President & CEO
October 2, 2018, 10:55 AM ET
New York, NY

Live and archived versions of the presentations will be available through the Inovio Investor Relations Events page at View Source

On August 21, 2018 Imago BioSciences, a clinical-stage pharmaceutical company developing novel anti-cancer therapies, reported that the Phase 1/2a clinical trial of IMG-7289 for the treatment of high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) has fully enrolled at 45 patients (Press release, Imago BioSciences, AUG 21, 2018, View Source [SID1234529013]). This study assessed the safety, pharmacokinetics, pharmacodynamics and anti-neoplastic activity of IMG-7289, an inhibitor of the epigenetic enzyme lysine-specific demethylase 1.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are extremely grateful to have worked with terrific investigators and staff that enrolled and cared for a population of patients in great need of therapeutic options," said Hugh Young Rienhoff, Jr. M.D., Imago’s Chief Executive Officer. "This study generated a wealth of knowledge about the pharmacokinetics, pharmacodynamics, and safety profile of our LSD1 inhibitor IMG-7289 as a single agent and in combination with ATRA. This study provides very clear guidance on how to use IMG-7289 at a variety of doses and in a variety of indications."

Upon the successful completion of the Phase 1 multiple ascending dose portion of the trial assessing IMG-7289 as a single agent, the study progressed into the Phase 2a expansion arm which evaluated the combination treatment regimen of IMG-7289 plus ATRA for extended dosing durations. Treatment of the final 2a expansion cohort remains ongoing.

About IMG-7289

IMG-7289 is a small molecule developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme regulating cytokine expression and shown to be vital in sustaining self-renewal in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, IMG-7289 demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies and models of myeloproliferative neoplasms as a single agent and in combination with other therapeutic agents. IMG-7289 also shows activity against solid tumors in combination with other agents in non-clinical models. IMG-7289 is an investigational agent currently being evaluated in a second Phase 1/2a clinical trial in high-risk myelofibrosis patients aged 18 or older is currently enrolling patients in both United States and Australia. (www.clinicaltrials.gov Identifier NCT03136185).

On August 21, 2018 Ichor Medical Systems, Inc. (Ichor) reported that its investigational TriGrid Delivery System (TriGrid) is being utilized in a Phase 1b/2 clinical trial to administer GX-188E, an investigational therapeutic HPV DNA vaccine developed by Genexine, Inc (Press release, Ichor Medical Systems, AUG 21, 2018, View Source [SID1234529014])., in patients with human papilloma virus (HPV)-induced advanced non-resectable cervical cancer, in combination with an anti-PD-1 therapy (NCT03444376).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cervical cancer is the fourth most common cancer affecting women worldwide and is almost always caused by infection with HPV. Preventative vaccines for cervical cancer are ineffective in women who are already infected with HPV, and despite advances in screening and HPV vaccination, a significant number of women develop advanced disease. Although chemotherapy is the standard first-line treatment for advanced cervical cancer, the prognosis remains poor and effective second line options are still needed.

Ichor’s patented TriGrid Delivery System uses electroporation to open pathways into cells to facilitate entry of a DNA vaccine into its intracellular site of action. The TriGrid has been utilized in >25 clinical studies, including randomized comparative studies demonstrating that administration of DNA vaccines with the TriGrid device significantly enhanced immune responses to the vaccines compared to conventional injection. A Phase 1 study using the TriGrid to deliver GX-188E in patients with high grade cervical intraepithelial neoplasia (CIN), a precancerous stage of cervical cancer, showed promising results with GX-188E demonstrating the ability to induce a tumor-specific immune response with evidence of lesion clearance (Nat Commun. 2014 Oct 30; 5: 5317).

Immuno-oncology is a rapidly evolving field of medicine designed to improve the ability of a patient’s immune system to detect and destroy tumors. The study has been initiated in Korea with plans to enroll up to 46 patients and was recently announced by Genexine.

Robert Bernard, Ichor Founder and CEO, stated, "Ichor’s TriGrid Delivery System is a platform technology used by an increasing number of Ichor partners for clinical delivery of their DNA vaccines where T-cell generation is a critical aspect of the prescribed immunotherapy. We are pleased through our Genexine partnership to expand TriGrid’s use into additional areas of immuno-oncology around the world."